Allianz Asset Management
CSTL icon

Allianz Asset Management’s Castle Biosciences CSTL Stock Holding History

Allianz Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.9M Buy
811,324
+189,025
+30% +$6.19M 0.02% 616
2025
Q4 		$24.2M Sell
622,299
-26,052
-4% -$840K 0.02% 527
2025
Q3 		$14.8M Sell
648,351
-65,391
-9% -$1.33M 0.02% 688
2025
Q2 		$14.6M Buy
713,742
+74,265
+12% +$1.37M 0.02% 686
2025
Q1 		$12.8M Buy
639,477
+317,103
+98% +$7.85M 0.02% 717
2024
Q4 		$8.59M Buy
322,374
+251,821
+357% +$7.67M 0.01% 802
2024
Q3 		$2.01M Buy
+70,553
New +$1.8M ﹤0.01% 1407
2020
Q2 		– Sell
-29,319
Closed -$874K – 2414
2020
Q1 		$874K Buy
+29,319
New +$885K ﹤0.01% 1849

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allianz Asset Management's CSTL Position: Q1 2026 in Review

Allianz Asset Management increased its Castle Biosciences (CSTL) stake by 30% in Q1 2026, buying an estimated $6.19M and bringing the position to 811,324 shares worth $19.9M. The position accounts for 0.02% of the portfolio, ranked #616.

Allianz Asset Management first reported a position in CSTL in Q1 2020 and has held it in 8 quarters since. The position peaked at $24.2M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Allianz Asset Management held 811,324 shares of Castle Biosciences worth $19.9M as of Q1 2026.
  • Allianz Asset Management bought 189,025 Castle Biosciences shares in Q1 2026, an estimated $6.19M.
  • Castle Biosciences made up 0.02% of Allianz Asset Management's portfolio in Q1 2026, its #616 holding.
  • Allianz Asset Management first reported a position in Castle Biosciences in Q1 2020 and has held it in 8 quarters since.
  • Allianz Asset Management's Castle Biosciences position peaked at $24.2M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.